Recently, it was reported that the GLS inhibitor CB-839 might increase the sensitivity of ovarian carcinoma cells to PI3K/mTOR inhibition [78], and several Phase I CB-839 clinical trials are listed (www.clinicaltrials.gov, last accessed on: 17 September 2019). Here, MTOR is linked to ovarian carcinoma.